Salvage therapy with bendamustine for temozolomide refractory recurrent anaplastic gliomas: a prospective phase II trial
Crossref DOI link: https://doi.org/10.1007/s11060-016-2241-7
Published Online: 2017-02-16
Published Print: 2017-02
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Chamberlain, Marc C.
Colman, Howard
Kim, Bryan T.
Raizer, Jeffrey
Funding for this research was provided by:
Teva Pharmaceutical Industries
License valid from 2017-02-01